
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc has demonstrated significant growth potential, highlighted by a 140% increase in Hepzato procedure volume in 2025, indicating increased physician utilization and adoption of its flagship product. The company's strong financial position is evident with a year-end cash balance of $91.0 million, reflecting operational efficiency and capacity for further investment in sales expansion. Management's strategy to increase referrals and enter new markets, along with promising clinical data from ongoing trials, positions Delcath for continued success and sustained adoption of its products in the oncology space.
Bears say
Delcath Systems Inc has revised its full-year revenue expectations downward to $83M-$85M from a prior estimate of $93M-$96M, primarily due to a notable slowdown in new site activations and a significant decrease in new patient starts linked to summer seasonality and competitive clinical trials. The company faces ongoing financial challenges, including expected discounts from the Medicaid National Drug Rebate Agreement, which have further pressured average revenue per kit and contributed to a cash flow negative situation. Additionally, with a lowered sales guidance for 2025 and persistent operational hurdles, the outlook for Delcath Systems remains concerning, indicating potential difficulty in achieving forecasted revenue levels.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares